Question 1

What is West Pharmaceutical Services's P/E ratio?

Accepted Answer

West Pharmaceutical Services (WST) P/E ratio is 47.8× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for West Pharmaceutical Services?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For West Pharmaceutical Services specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is West Pharmaceutical Services's P/E ratio high or low?

Accepted Answer

West Pharmaceutical Services's P/E ratio of 47.8× is above its own 5-year average of 42.7× and above the sector median of 24.2×. That places the current reading at the 72th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is West Pharmaceutical Services's historical P/E ratio range?

Accepted Answer

In the available daily series, West Pharmaceutical Services (WST) P/E ratio has ranged from a low of 14.3× in 2009 to a high of 72.5× in 2021. The 5-year average is 42.7× and the 5-year median is 44.3×.

Question 7

What was West Pharmaceutical Services's P/E ratio in 2025?

Accepted Answer

West Pharmaceutical Services (WST) P/E ratio at the end of 2025 was 40.3×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does West Pharmaceutical Services's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$19.9B	$494M	40.3×	-8.2×	Dec 31, 2025
2024	$23.9B	$493M	48.5×	+4.6×	Dec 31, 2024
2023	$26.1B	$593M	44.0×	+14.1×	Dec 31, 2023
2022	$17.5B	$586M	29.9×	-22.9×	Dec 31, 2022
2021	$34.9B	$662M	52.8×	-7.8×	Dec 31, 2021
2020	$21B	$346M	60.6×	+14.5×	Dec 31, 2020
2019	$11.1B	$242M	46.1×	+11.1×	Dec 31, 2019
2018	$7.24B	$207M	35.0×	-14.4×	Dec 31, 2018
2017	$7.32B	$148M	49.4×	+6.1×	Dec 31, 2017
2016	$6.21B	$144M	43.3×	-2.3×	Dec 31, 2016
2015	$4.35B	$95.6M	45.5×	+15.7×	Dec 31, 2015
2014	$3.8B	$127M	29.9×	-0.8×	Dec 31, 2014
2013	$3.44B	$112M	30.6×	+7.4×	Dec 31, 2013
2012	$1.87B	$80.7M	23.2×	+6.1×	Dec 31, 2012
2011	$1.29B	$75.4M	17.1×	-4.1×	Dec 31, 2011
2010	$1.38B	$65.3M	21.1×	+3.3×	Dec 31, 2010
2009	$1.3B	$72.6M	17.9×	+3.5×	Dec 31, 2009
2008	$1.24B	$85.9M	14.4×	-4.1×	Dec 31, 2008
2007	$1.31B	$70.7M	18.5×	-6.5×	Dec 31, 2007
2006	$1.68B	$67.1M	25.0×	+7.5×	Dec 31, 2006
2005	$795M	$45.6M	17.4×	-22.1×	Dec 31, 2005
2004	$767M	$19.4M	39.6×	+23.9×	Dec 31, 2004
2003	$499M	$31.9M	15.6×	-3.6×	Dec 31, 2003
2002	$353M	$18.4M	19.2×	—	Dec 31, 2002


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for West Pharmaceutical Services (WST) 2002-2026

P/E Ratio daily chart for West Pharmaceutical Services (WST)

Historical P/E Ratio for West Pharmaceutical Services (WST) from 2002 to 2025

About P/E Ratio at West Pharmaceutical Services (WST)

West Pharmaceutical Services P/E Ratio by Year

West Pharmaceutical Services P/E Ratio 2025: 40.3×

West Pharmaceutical Services P/E Ratio 2024: 48.5×

West Pharmaceutical Services P/E Ratio 2023: 44.0×

West Pharmaceutical Services P/E Ratio 2022: 29.9×

West Pharmaceutical Services P/E Ratio 2021: 52.8×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

West Pharmaceutical Services (WST) Key Financials